tetano
Editor, Senior Moderator
Radiologia (Engl Ed)
. 2024 Apr:66 Suppl 1:S47-S56.
doi: 10.1016/j.rxeng.2023.10.002. Epub 2024 Mar 4. Persistent pulmonary abnormalities after 18 months of SARS-CoV-2 pneumonia
C Valenzuela[SUP] 1 [/SUP], L de la Fuente[SUP] 2 [/SUP], S Hernández[SUP] 2 [/SUP], M J Olivera[SUP] 2 [/SUP], C Molina[SUP] 2 [/SUP], N Montes[SUP] 3 [/SUP], C Benavides[SUP] 2 [/SUP], P Caballero[SUP] 4 [/SUP]
Affiliations
Objective: To describe persistent pulmonary abnormalities detected on HRCT after 18 months of SARS-CoV-2 pneumonia, and to determine their extension and correlation with pulmonary function.
Patients and methods: A prospective cross-sectional study with an initial cohort of 90 patients in follow-up due to persisting lung abnormalities on imaging, functional respiratory impairment and/or respiratory symptoms. Of these, 31 (34%) were selected for analysis due to the persistence of their lung abnormalities on HRCT at 18 months after infection. A double reading was performed for each HRCT (62 observations).
Results: Of the 31 patients included: 20 (65%) were men; mean age was 67 years; 17 (55%) were smokers/ex-smokers. The mean hospitalisation time was 38 days. Eighteen (58%) patients were admitted to intensive care units. Five patients (16%) suffered an acute pulmonary thromboembolism and three (9.7%) had a pneumothorax. The mean time between the onset of pneumonia and the follow-up HRCT was 20.34 months. Nineteen percent of patients suffered from total lung function abnormalities; and ground-glass opacities and reticulation were present in 12% and 4.5% respectively. The findings of the 62 readings were: ground-glass opacities (100%), reticulation (83%), subpleural curvilinear lines (62%), parenchymal bands (34%), traction bronchiectasis (69%), displacement of vessels/fissures (46%) and honeycombing (4.9%). Pulmonary function 18 months after the acute episode revealed a mean FVC of 92% of predicted value, with an FVC < 80% of predicted value in 11 patients (35.4%). Mean DLCO was 71% of predicted value, with a DLCO < 80% in 22 patients (70%). We observed a statistically significant relationship between total lung function abnormalities on HRCT and FVC (P < 0.05), and a trend towards statistical significance with DLCO (P = 0.051); there was a statistically significant relationship between the presence of ground-glass opacities and FEV1/FVC (P < 0.01). The relationships between reticulation and FVC, FVC%, FEV1, FEV1% and DLCO% were also considered statistically significant (P < 0.05).
Conclusion: Persistent interstitial lung abnormalities are seen on HRCT for a subset of patients infected with SARS-CoV-2 pneumonia. Seventy percent of these patients suffered a slight decrease in DLCO.
Keywords: COVID-19; Lung HRCT; Post-COVID-fibrosis; Pulmonary sequelae; SARS-CoV-2; Secuelas pulmonares; TCAR pulmonar.
. 2024 Apr:66 Suppl 1:S47-S56.
doi: 10.1016/j.rxeng.2023.10.002. Epub 2024 Mar 4. Persistent pulmonary abnormalities after 18 months of SARS-CoV-2 pneumonia
C Valenzuela[SUP] 1 [/SUP], L de la Fuente[SUP] 2 [/SUP], S Hernández[SUP] 2 [/SUP], M J Olivera[SUP] 2 [/SUP], C Molina[SUP] 2 [/SUP], N Montes[SUP] 3 [/SUP], C Benavides[SUP] 2 [/SUP], P Caballero[SUP] 4 [/SUP]
Affiliations
- PMID: 38642961
- DOI: 10.1016/j.rxeng.2023.10.002
Objective: To describe persistent pulmonary abnormalities detected on HRCT after 18 months of SARS-CoV-2 pneumonia, and to determine their extension and correlation with pulmonary function.
Patients and methods: A prospective cross-sectional study with an initial cohort of 90 patients in follow-up due to persisting lung abnormalities on imaging, functional respiratory impairment and/or respiratory symptoms. Of these, 31 (34%) were selected for analysis due to the persistence of their lung abnormalities on HRCT at 18 months after infection. A double reading was performed for each HRCT (62 observations).
Results: Of the 31 patients included: 20 (65%) were men; mean age was 67 years; 17 (55%) were smokers/ex-smokers. The mean hospitalisation time was 38 days. Eighteen (58%) patients were admitted to intensive care units. Five patients (16%) suffered an acute pulmonary thromboembolism and three (9.7%) had a pneumothorax. The mean time between the onset of pneumonia and the follow-up HRCT was 20.34 months. Nineteen percent of patients suffered from total lung function abnormalities; and ground-glass opacities and reticulation were present in 12% and 4.5% respectively. The findings of the 62 readings were: ground-glass opacities (100%), reticulation (83%), subpleural curvilinear lines (62%), parenchymal bands (34%), traction bronchiectasis (69%), displacement of vessels/fissures (46%) and honeycombing (4.9%). Pulmonary function 18 months after the acute episode revealed a mean FVC of 92% of predicted value, with an FVC < 80% of predicted value in 11 patients (35.4%). Mean DLCO was 71% of predicted value, with a DLCO < 80% in 22 patients (70%). We observed a statistically significant relationship between total lung function abnormalities on HRCT and FVC (P < 0.05), and a trend towards statistical significance with DLCO (P = 0.051); there was a statistically significant relationship between the presence of ground-glass opacities and FEV1/FVC (P < 0.01). The relationships between reticulation and FVC, FVC%, FEV1, FEV1% and DLCO% were also considered statistically significant (P < 0.05).
Conclusion: Persistent interstitial lung abnormalities are seen on HRCT for a subset of patients infected with SARS-CoV-2 pneumonia. Seventy percent of these patients suffered a slight decrease in DLCO.
Keywords: COVID-19; Lung HRCT; Post-COVID-fibrosis; Pulmonary sequelae; SARS-CoV-2; Secuelas pulmonares; TCAR pulmonar.